Selected research
Industry Research
Parkinson's Disease Treatments Industry Research Report 2026
Market perspective
The global Parkinson's Disease Treatments market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Parkinson's Disease Treatments market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Parkinson's Disease Treatments market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Parkinson's Disease Treatments market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Parkinson's Disease Treatments include GSK, Teva, Sun Pharma, Novartis, Merck, Abbvie, Wockhardt, UCB and Lundbeck, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Parkinson's Disease Treatments market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Parkinson's Disease Treatments.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Parkinson's Disease Treatments Market by Company
GSK
Teva
Sun Pharma
Novartis
Merck
Abbvie
Wockhardt
UCB
Lundbeck
Impax
Boehringer Ingelheim
Bausch Health
Acadia
Parkinson's Disease Treatments Segment by Type
COMT Inhibitors Anticholinergics
MAO-B Inhibitors
Apomorphine
Dopamine Agonists
Glutamate Antagonist
Levodopa
Other Drugs
Parkinson's Disease Treatments Segment by Application
Hospitals
Healthcare Institutes
Others
Parkinson's Disease Treatments Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson's Disease Treatments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson's Disease Treatments and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson's Disease Treatments.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Parkinson's Disease Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- COMT Inhibitors Anticholinergics
- MAO-B Inhibitors
- Apomorphine
- Dopamine Agonists
- Glutamate Antagonist
- Levodopa
- Other Drugs
Applications
- Hospitals
- Healthcare Institutes
- Others
Companies covered
- GSK
- Teva
- Sun Pharma
- Novartis
- Merck
- Abbvie
- Wockhardt
- UCB
- Lundbeck
- Impax
- Boehringer Ingelheim
- Bausch Health
- Acadia
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Parkinson's Disease Treatments by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 COMT Inhibitors Anticholinergics
- 2.2.3 MAO-B Inhibitors
- 2.2.4 Apomorphine
- 2.2.5 Dopamine Agonists
- 2.2.6 Glutamate Antagonist
- 2.2.7 Levodopa
- 2.2.8 Other Drugs
- 2.3 Parkinson's Disease Treatments by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Healthcare Institutes
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Parkinson's Disease Treatments Breakdown Data by Type
- 3.1 Global Parkinson's Disease Treatments Historic Market Size by Type (2021-2026)
- 3.2 Global Parkinson's Disease Treatments Forecasted Market Size by Type (2027-2032)
4 Parkinson's Disease Treatments Breakdown Data by Application
- 4.1 Global Parkinson's Disease Treatments Historic Market Size by Application (2021-2026)
- 4.2 Global Parkinson's Disease Treatments Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Parkinson's Disease Treatments Market Perspective (2021-2032)
- 5.2 Global Parkinson's Disease Treatments Growth Trends by Region
- 5.2.1 Global Parkinson's Disease Treatments Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Parkinson's Disease Treatments Historic Market Size by Region (2021-2026)
- 5.2.3 Parkinson's Disease Treatments Forecasted Market Size by Region (2027-2032)
- 5.3 Parkinson's Disease Treatments Market Dynamics
- 5.3.1 Parkinson's Disease Treatments Industry Trends
- 5.3.2 Parkinson's Disease Treatments Market Drivers
- 5.3.3 Parkinson's Disease Treatments Market Challenges
- 5.3.4 Parkinson's Disease Treatments Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Parkinson's Disease Treatments Players by Revenue
- 6.1.1 Global Top Parkinson's Disease Treatments Players by Revenue (2021-2026)
- 6.1.2 Global Parkinson's Disease Treatments Revenue Market Share by Players (2021-2026)
- 6.2 Global Parkinson's Disease Treatments Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Parkinson's Disease Treatments Head Office and Area Served
- 6.4 Global Parkinson's Disease Treatments Players, Product Type & Application
- 6.5 Global Parkinson's Disease Treatments Manufacturers Established Date
- 6.6 Global Parkinson's Disease Treatments Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Parkinson's Disease Treatments Market Size (2021-2032)
- 7.2 North America Parkinson's Disease Treatments Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 7.4 North America Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Parkinson's Disease Treatments Market Size (2021-2032)
- 8.2 Europe Parkinson's Disease Treatments Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 8.4 Europe Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Parkinson's Disease Treatments Market Size (2021-2032)
- 9.2 Asia-Pacific Parkinson's Disease Treatments Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Parkinson's Disease Treatments Market Size (2021-2032)
- 10.2 South America Parkinson's Disease Treatments Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 10.4 South America Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Parkinson's Disease Treatments Market Size (2021-2032)
- 11.2 Middle East & Africa Parkinson's Disease Treatments Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Parkinson's Disease Treatments Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GSK
- 12.1.1 GSK Company Information
- 12.1.2 GSK Business Overview
- 12.1.3 GSK Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.1.4 GSK Parkinson's Disease Treatments Product Portfolio
- 12.1.5 GSK Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.2.4 Teva Parkinson's Disease Treatments Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Sun Pharma
- 12.3.1 Sun Pharma Company Information
- 12.3.2 Sun Pharma Business Overview
- 12.3.3 Sun Pharma Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.3.4 Sun Pharma Parkinson's Disease Treatments Product Portfolio
- 12.3.5 Sun Pharma Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.4.4 Novartis Parkinson's Disease Treatments Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Merck
- 12.5.1 Merck Company Information
- 12.5.2 Merck Business Overview
- 12.5.3 Merck Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.5.4 Merck Parkinson's Disease Treatments Product Portfolio
- 12.5.5 Merck Recent Developments
- 12.6 Abbvie
- 12.6.1 Abbvie Company Information
- 12.6.2 Abbvie Business Overview
- 12.6.3 Abbvie Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.6.4 Abbvie Parkinson's Disease Treatments Product Portfolio
- 12.6.5 Abbvie Recent Developments
- 12.7 Wockhardt
- 12.7.1 Wockhardt Company Information
- 12.7.2 Wockhardt Business Overview
- 12.7.3 Wockhardt Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.7.4 Wockhardt Parkinson's Disease Treatments Product Portfolio
- 12.7.5 Wockhardt Recent Developments
- 12.8 UCB
- 12.8.1 UCB Company Information
- 12.8.2 UCB Business Overview
- 12.8.3 UCB Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.8.4 UCB Parkinson's Disease Treatments Product Portfolio
- 12.8.5 UCB Recent Developments
- 12.9 Lundbeck
- 12.9.1 Lundbeck Company Information
- 12.9.2 Lundbeck Business Overview
- 12.9.3 Lundbeck Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.9.4 Lundbeck Parkinson's Disease Treatments Product Portfolio
- 12.9.5 Lundbeck Recent Developments
- 12.10 Impax
- 12.10.1 Impax Company Information
- 12.10.2 Impax Business Overview
- 12.10.3 Impax Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.10.4 Impax Parkinson's Disease Treatments Product Portfolio
- 12.10.5 Impax Recent Developments
- 12.11 Boehringer Ingelheim
- 12.11.1 Boehringer Ingelheim Company Information
- 12.11.2 Boehringer Ingelheim Business Overview
- 12.11.3 Boehringer Ingelheim Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.11.4 Boehringer Ingelheim Parkinson's Disease Treatments Product Portfolio
- 12.11.5 Boehringer Ingelheim Recent Developments
- 12.12 Bausch Health
- 12.12.1 Bausch Health Company Information
- 12.12.2 Bausch Health Business Overview
- 12.12.3 Bausch Health Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.12.4 Bausch Health Parkinson's Disease Treatments Product Portfolio
- 12.12.5 Bausch Health Recent Developments
- 12.13 Acadia
- 12.13.1 Acadia Company Information
- 12.13.2 Acadia Business Overview
- 12.13.3 Acadia Revenue in Parkinson's Disease Treatments Business (2021-2026)
- 12.13.4 Acadia Parkinson's Disease Treatments Product Portfolio
- 12.13.5 Acadia Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst